BFM
AMAM

Boothbay Fund Management’s Ambrx Biopharma Inc AMAM Stock Holding History

Boothbay Fund Management’s Portfolio AMAM Stock Details AMAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13,422
Closed -$263K – 2276
2021
Q2 		$263K Buy
+13,422
New +$229K 0.01% 1363

Other funds holding AMAM

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Boothbay Fund Management's AMAM Position: Q3 2021 in Review

Boothbay Fund Management sold out of Ambrx Biopharma Inc (AMAM) in Q3 2021, closing a stake of 13,422 shares — an estimated $263K sold.

Boothbay Fund Management first reported a position in AMAM in Q2 2021 and held it in 1 quarter. The position peaked at $263K in Q2 2021. 15 funds tracked by Wall St. Rank hold AMAM as of Q3 2021.

  • Boothbay Fund Management reported no remaining Ambrx Biopharma Inc position as of Q3 2021 after selling out during the quarter.
  • Boothbay Fund Management sold 13,422 Ambrx Biopharma Inc shares in Q3 2021, an estimated $263K.
  • Boothbay Fund Management first reported a position in Ambrx Biopharma Inc in Q2 2021 and held it in 1 quarter.
  • Boothbay Fund Management's Ambrx Biopharma Inc position peaked at $263K in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q3 2021.

Based on Boothbay Fund Management's 13F filing for Q3 2021, filed 15 Nov 2021.